GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in chinese population

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3465-3469

  Li, Hui Yan ^a   Ge, Xin ^b   Huang, Guang Ming ^b   Li, Kai Yu ^b   Zhao, Jing Quan ^b   Yu, Xi Miao ^b   Bi, Wen Si ^b   Wang, Yu Lin ^c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Second Hospital of Heilongjiang Province   (China)

^c MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Chemotherapy; Colorectal cancer; ERCC1 Asn118Asn; ERCC2 Lys751Gln; GSTP1

Indexed keywords

EID: 84873603099     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3465     Document Type: Article

References (29)

1. Baek SK, Kim SY, Lee JJ, et al (2006). Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat, 38, 19-24.
2. Cao C, Zhang YM, Wang R, et al (2011). Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl), 124, 2203-8.
3. Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37.
4. Han X, Xing Q, Li Y, et al (2012). Study on the DNA Repair Gene XRCC1 and XRCC3 Polymorphism in Prediction and Prognosis of Hepatocellular Carcinoma risk. Hepatogastroenterology, 59, doi: 10.5754/hge12096. [Epub ahead of print]
5. International Agency for Research on Cancer (2008). Colorectal Cancer Incidence and Mortality Worldwide in 2008. 2011, http://globocan.iarc.fr.
6. Ishibashi K, Okada N, Tajima Y, et al (2011). Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2 (ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase (MTHFD) in the primary lesion of colorectal cancer. Gan To Kagaku Ryoho, 38, 2220-3.
7. Jun L, Haiping Z, Beibei Y (2009). Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly, 139, 724-8.
8. Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer, 8, 148.
9. Kim KH, Kwon HC, Oh SY, et al (2011). Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers, 16, 74-82.
10. Kweekel DM, Gelderblom H, Antonini NF, et al (2009). Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer, 45, 572-8.
11. Kweekel DM, Gelderblom H, Guchelaar HJ (2005). Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev, 31, 90-105.
12. Kwee S, Song MA, Cheng I, et al (2012). Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci, 5, 65-70.
13. Lascorz J, Bevier M, Schönfels WV, et al (2012). Polymorphisms in the mitochondrial oxidative phosphorylation chain genes as prognostic markers for colorectal cancer. BMC Med Genet, 13, 31.
14. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol, 29, 4555-60.
15. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.
16. Noda E, Maeda K, Inoue T, et al (2012). Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology, 59, 130-3.
17. Rajaraman P, Bhatti P, Doody MM, et al (2008). Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer, 123, 2713-6.
18. Reed E (2005). ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 11, 6100-2.
19. Rouissi K, Bahria IB, Bougatef K, et al (2011). The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer, 11, 101.
20. Sato K (1989). Glutathione S-transferases as markers of preneoplasia and neoplasia. Adv Cancer Res, 52, 205-55.
21. Sharma RA, Dianov GL (2007). Targeting base excision repair to improve cancer therapies. Mol Aspects Med, 28, 345-74.
22. Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936-42.
23. Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU / oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
24. Storm HH, Engholm G, Hakulinen T, et al (2010). Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol, 49, 532-44.
25. Sun JM, Ahn MJ, Park MJ, et al (2011). Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 80, 655-60.
26. Townsend DM, Tew KD (2003). The role of glutathione-Stransferase in anti-cancer drug resistance. Oncogene, 22, 7369-75.
27. Woolston CM, Zhang L, Storr SJ, et al (2012). The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Mod Pathol, Apr 6.
28. Zha Y, Cun Y, Zhang Q, et al (2012). Prognostic Value of Expression of Kit67, p53, TopoIIa and GSTP1 for Curatively Resected Advanced Gastric Cancer Patients Receiving Adjuvant Paclitaxel plus Capecitabine Chemotherapy. Hepatogastroenterology, 59, 1327-32.
29. Zhao Y, Deng X, Wang Z, et al (2012). Genetic Polymorphisms of DNA Repair Genes XRCC1 and XRCC3 and Risk of Colorectal Cancer in Chinese Population. Asian Pac J Cancer Prev, 13, 665-9.